Voices
Karine Tawagi: Real-World Outcomes mHSPC for Triplet With Daro vs Abi
Karine Tawagi/X

Karine Tawagi: Real-World Outcomes mHSPC for Triplet With Daro vs Abi

Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared a post on X:

“Abstracts for ASCOGU26

Poster: real-world outcomes mHSPC for triplet with Daro (ARASENS) vs Abi (PEACE1) by Alicia Morgans

Retrospective review 592 pts

Pts receiving Daro triplet had improved outcomes over Abi triplet, inc. TTD, time to mCRPC/death, PSA R, OS..”

Karine Tawagi: Real-World Outcomes mHSPC for Triplet With Daro vs Abi

Other articles featuring Karine Tawagi on OncoDaily.

Alicia Morgans ASCOGU26 cancer Karine Tawagi Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) mHSPC OncoDaily Oncology University of Illinois Chicago